Indicator Explainer
FGFR2 Gene
This gene plays a role in mitogenesis and differentiation and mutations in the gene are associated with craniosynostotic syndromes and bone malformations.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C19931. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — FGFR2 Gene (C19931)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C19931. NCI definition, reproduced without modification under CC BY 4.0.
- Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial. — Br J Cancer, 2026-06-23 (PMID 42337043; literature)
- Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301. — ESMO Open, 2026-03-17 (PMID 41850040; literature)
- Intronic Single Nucleotide Polymorphisms in FGFR2 Gene Association With Non-Syndromic Mandibular Retrognathism. — Orthod Craniofac Res, 2026-01-12 (PMID 41524290; literature)